Health Science Journal

  • ISSN: 1108-7366
  • Journal h-index: 51
  • Journal CiteScore: 10.69
  • Journal Impact Factor: 9.13
  • Average acceptance to publication time (5-7 days)
  • Average article processing time (30-45 days) Less than 5 volumes 30 days
    8 - 9 volumes 40 days
    10 and more volumes 45 days
Awards Nomination 20+ Million Readerbase
Indexed In
  • Genamics JournalSeek
  • China National Knowledge Infrastructure (CNKI)
  • CiteFactor
  • CINAHL Complete
  • Scimago
  • Electronic Journals Library
  • Directory of Research Journal Indexing (DRJI)
  • EMCare
  • OCLC- WorldCat
  • University Grants Commission
  • Geneva Foundation for Medical Education and Research
  • Euro Pub
  • Google Scholar
  • Secret Search Engine Labs
Share This Page
Recommended Webinars & Conferences

International Conference on Oral Health and Dentistry

Kuala Lumpur, Malaysia

Treatment and Secondary Prophylaxis of Venous Thromboembolism with Anti-XA in Patients with Severe Hereditary Thrombophilia

XX Congresso Regionale FADOI CAMPANIA: Non ci siamo mai fermati
Italy 2021

Madonna P*, Guida A, Mangiacapra S, Papa G, Amitrano M and Tufano A

UOC Medicina, Generale Ospedale Del Mare ASL Na1 Centro, Napoli, Italy
UOC Medicina Interna, AORN Moscati, Avellino, Italy
Dipartimento di Medicina Clinica, e Chirurgia Universit�?�?�?  degli studi di Napoli Federico II, Napoli, Italy

Posters & Accepted Abstracts: Health Sci J


Deficiency of protein C, protein S, antithrombin III and homozygosity or combined heterozygosity for factor V Leiden and F II 20210A mutation represent severe hereditary thrombophilia (SHT) and are associated with higher risk of early onset venous thromboembolism (VTE). In literature few papers have described the efficacy and safety of therapy with anti-Xa in VTE occurring in patients with SHT. In our setting, since March 2014, we identified 21 patients (11 M and 10 F) who have suffered from early onset VTE treated with anti-X in all cases (13 Rivaroxaban, 4 Apixaban, 4 Edoxaban). Among them 3 AT III deficiency, 4 PC deficiency, 4 PS deficiency, 3 homozigosity for FV Leiden, 2 homozigosity for F II 20210A and1 combined heterozygosity for FV Leiden and F II 20210A were detected. Two patients underwent therapy for a variable period of 12-24 months before stopping, one, after 24 months, shifted to anti-FX low dose therapy, all the others, were assigned to a lifelong therapy with full-dose therapy. During the follow up, either VTE recurrences or haemorragic episodes were not observed. This report describes the efficacy and safety of therapy with anti-Xa in the treatment and secondary prophylaxis of VTE in patients with SHT.